More precise cancer treatments with digital solutions
Ketil Widerberg, general manager of Oslo Cancer Cluster, gives his perspectives on why EHiN and digital health are important for faster development of new cancer treatments in Norway.
Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.
We are excited to welcome Björn Carlsson. Björn comes from a comprehensive scientific and regulatory background and has extensive experience in ATMPs. We have no doubt that he will be a valuable asset to our team.
The second-year class of the Researcher Programme at Ullern Upper Secondary School has been assigned new mentors for the school year 2020/2021. The first meeting with the mentors was about how the road to becoming a researcher or doctor or other occupation can be diverse and take many different routes.
In this article, we shine the spotlight on Dr. Brian Edwards, one of our most seasoned Principal Consultants who has been with NDA since 2007. He specialises in Pharmacovigilance, quality management, and all aspects of safety compliance, risk management, QPPV services, and clinical trial safety.
Funds for personalized medicine, clinical trials, mature clusters, and digitalisation – these are some of the main points for cancer innovation in the newly released state budget.
The workshop in Time Resolved Structural Biology organized by LINXS will be held as an online workshop November 23-25, 2020, each day there will be a session between 13h and 18h (CET; Central European Time). We have opened up the workshop for a larger number of participants so we welcome new registrations!
Our member Vaccibody signs multi-million-dollar agreement one week before the company is expected on the stock exchange.
InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study have been published in the high-impact medical journal The Lancet Gastroenterology and Hepatology.
In this whitepaper, Helen provides tips and good practices for remote audits as an alternative method to conducting traditional on-site audit.
Tero Lahti adds to Blue Industry Park’s repertoire his long and varied experience consisting of things like Meyer Turku’s 300-million-euro investment project.
Oslo Cancer Cluster (OCC) Innovation Park and Incubator plans to expand by 5o ooo m² in the coming years. The goal is to create an international innovation hub in cancer. Why? Because personalized medicine is changing cancer innovation.